Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT02721004
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.

Study Details

This is an open-label, non-interventional study to evaluate efficacy and safety in rheumatoid arthritis participants receiving tocilizumab as per the product label.

Key Dates

Start date
Mar 31, 2009
Status verified
Jul 2016
Primary completion
Dec 31, 2014
Completion
Dec 31, 2014

Study Design

Enrollment
592 participants (actual)

Arms

  • Arm: Rheumatoid arthritis participants
    Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.

Primary Outcome Measure

Disease Activity Score Based on 28-joints Count (DAS28) [ Time Frame: Month 12 ]

Related Studies